| Entry |
|
|---|
| Name |
Brolucizumab (USAN/INN);
Brolucizumab (genetical recombination) (JAN);
Brolucizuab-dbll;
Beovu (TN)
|
|---|
| Product |
|
|---|
| Formula |
C1164H1768N310O372S8
|
|---|
| Exact mass |
26296.6724
|
|---|
| Mol weight |
26312.8665
|
|---|
| Sequence |
MEIVMTQSPS TLSASVGDRV IITCQASEII HSWLAWYQQK PGKAPKLLIY LASTLASGVP
SRFSGSGSGA EFTLTISSLQ PDDFATYYCQ NVYLASTNGA NFGQGTKLTV LGGGGGSGGG
GSGGGGSGGG GSEVQLVESG GGLVQPGGSL RLSCTASGFS LTDYYYMTWV RQAPGKGLEW
VGFIDPDDDP YYATWAKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAG GDHNSGWGLD
IWGQGTLVTV SS
(Disulfide bridge: 24-89, 154-228) |
|---|
| Type |
Peptide |
|---|
| Remark |
|
|---|
| Efficacy |
Age-related macular degeneration therapeutic agent, Anti-VEGF antibody |
|---|
| Disease |
Age-related macular degeneration [DS: H00821] |
|---|
| Comment |
Monoclonal antibody
Treatment of wet age-related macular degeneration
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01L OCULAR VASCULAR DISORDER AGENTS
S01LA Antineovascularisation agents
S01LA06 Brolucizumab
D11083 Brolucizumab (USAN/INN) <US>
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Growth factors (RTK-binding)
VEGFA
D11083 Brolucizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11083
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11083
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
